<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880538</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00146589</org_study_id>
    <nct_id>NCT04880538</nct_id>
  </id_info>
  <brief_title>Enteric Neural Precursor Cells (ENPC) in the Human Gut</brief_title>
  <official_title>Enteric Neural Precursor Cells (ENPC) in the Human Gut - Identification of Molecular Signature and Characterization of Their Proliferative &amp; Neurogenic Potential Using Surgical/Endoscopic Biopsies in Vitro</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim is to acquire human tissues to (a) understand the structure and organization of&#xD;
      the human Enteric Nervous System; (b) perform a molecular transcriptomic profile of&#xD;
      individual cells residing in the human gut; (c) study the turnover rates of individual cell&#xD;
      types by Fluorescence-activated cell sorting-aided C14 dating of cells; and finally (d)&#xD;
      culture the human gut-derived cells characterize the human adult enteric neural stem cell and&#xD;
      study its potential for Neuro-glial differentiation. This study will advance our knowledge of&#xD;
      the the cellular and molecular correlates of changes in the Enteric Nervous System that are&#xD;
      associated with disorders of motility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (i) To study the structure and organization of the human Enteric Nervous System by tissue&#xD;
      clarification, immunofluorescence, and 2-photon and light-sheet microscopy.&#xD;
&#xD;
      (ii) To find out the molecular signature that defines various gastrointestinal cells that&#xD;
      include the neurons, glia, precursor cells within the Enteric Nervous System and cells&#xD;
      associated with the Enteric Nervous System, such as Interstitial Cell of Cajal and&#xD;
      macrophages in the human whole gut surgical resection and full thickness endoscopic&#xD;
      resection-derived tissues using single cell RNA sequencing and analyses.&#xD;
&#xD;
      (iii) To isolate these cells and study their proliferative and neurogenic potential in vitro&#xD;
      and on transplantation into the gut tissue of immunodeficient mice.&#xD;
&#xD;
      (iv) To time stamp and determine the age of Enteric Nervous System cells in adults and&#xD;
      determine whether different enteric disease states alter the cycling times of these cells.&#xD;
&#xD;
      (v) To use gut specimens derived from surgical resections and full thickness endoscopic&#xD;
      resection-derived tissues for&#xD;
&#xD;
        1. Generating ex vivo preps to study and understand the electrophysiological properties of&#xD;
           the gut wall and&#xD;
&#xD;
        2. Generating cultured ex vivo preps to understand the interaction between enteric&#xD;
           extracellular matrix and cells of the Enteric Nervous System.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visualization of the network of Nestin+ cells in human gut resection specimens.</measure>
    <time_frame>Up to one year</time_frame>
    <description>Presence or absence of antibodies (including but not limited to) specific to Nestin, p75 neurotrophin receptor, pan-neuronal antibodies, pan-glial antibodies, antibodies against Interstitial Cells of Cajal.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Gastrointestinal Dysmotility</condition>
  <arm_group>
    <arm_group_label>Asymptomatic patients for any motility disorder</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with gastrointestinal dysmotility</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic procedure</intervention_name>
    <description>Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.</description>
    <arm_group_label>Asymptomatic patients for any motility disorder</arm_group_label>
    <arm_group_label>Patients with gastrointestinal dysmotility</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with gastrointestinal diseases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English speaking patients in the age range 18 - 100.&#xD;
&#xD;
          -  Patients suffering from Irritable Bowel Syndrome, Inflammatory Bowel Disease,&#xD;
             Diabetes, Gastroparesis, will be included.&#xD;
&#xD;
          -  Patients suffering from Collagen disorders such as Alport Syndrome, Ehlers-Danlos&#xD;
             Syndrome, Goodpasture Syndrome.&#xD;
&#xD;
          -  Patients suffering from plexiform neurofibromas.&#xD;
&#xD;
          -  Patients with bariatric surgery.&#xD;
&#xD;
          -  Patients with appendicitis.&#xD;
&#xD;
          -  Patients with scleroderma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from HIV, Hepatitis C, and other infectious diseases that require&#xD;
             the handling of tissues in a Bio-safety level 3 environment.&#xD;
&#xD;
          -  Patients suffering from infectious enteric disorders.&#xD;
&#xD;
          -  Patients without any Gastrointestinal disorders (i.e. healthy volunteers).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pankaj J Pasricha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pankaj J Pasricha, MD</last_name>
    <phone>4105501793</phone>
    <email>pasricha@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillermo A Barahona, MD</last_name>
    <phone>4106038343</phone>
    <email>gbaraho1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pankaj Pasricha, MD</last_name>
      <phone>410-550-1793</phone>
      <email>pasricha@jhu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Guillermo Barahona, MD</last_name>
      <phone>4106038343</phone>
      <email>gbaraho1@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

